Capecitabine in the treatment of colorectal cancer

References

• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin.55(2), 74–108 (2005).
   PubMed Web of Science ®Google Scholar
• Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J. Clin.49(1), 8–31, (1999).
   PubMed Web of Science ®Google Scholar
• Wingo PA, Ries LA, Parker SL, Heath CW Jr. Long-term cancer patient survival in the United States. Cancer Epidemiol. Biomarkers Prev.7(4), 271–282 (1998).
   PubMed Web of Science ®Google Scholar
• Midgley R, Kerr D. Colorectal cancer. Lancet353(9150), 391–399 (1999).
   PubMed Web of Science ®Google Scholar
• Obrand DI, Gordon PH. Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Dis. Colon Rectum40(1), 15–24 (1997).
   PubMed Web of Science ®Google Scholar
• Cunningham D, Findlay M. The chemotherapy of colon cancer can no longer be ignored. Eur. J. Cancer29A(15), 2077–2079 (1993).
   PubMed Web of Science ®Google Scholar
• Blijham GH. Chemotherapy of colorectal cancer. Anticancer Drugs2(3), 233–245 (1991).
   PubMed Web of Science ®Google Scholar
• de Gramont A, Bosset JF, Milan C et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J. Clin. Oncol.15(2), 808–815 (1997).
   PubMed Web of Science ®Google Scholar
• Mayer RJ. Chemotherapy for metastatic colorectal cancer. Cancer70(5 Suppl.), 1414–1424 (1992).
   PubMed Web of Science ®Google Scholar
• Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J. Clin. Oncol.7(4), 425–432 (1989).
   PubMed Web of Science ®Google Scholar
• Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br. Med. J.306(6880), 752–755 (1993).
   PubMed Web of Science ®Google Scholar
• Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group in Cancer. J. Clin. Oncol.16(1), 301–308 (1998).
   PubMed Web of Science ®Google Scholar
• Miwa M, Ura M, Nishida M et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur. J. Cancer34(8), 1274–1281 (1998).
   PubMed Web of Science ®Google Scholar
• Schuller J, Cassidy J, Dumont E et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother. Pharmacol.45(4), 291–297 (2000).
   PubMed Web of Science ®Google Scholar
• Sobrero A, Guglielmi A, Grossi F, Puglisi F, Aschele C. Mechanism of action of fluoropyrimidines: relevance to the new developments in colorectal cancer chemotherapy. Semin. Oncol.27(5 Suppl. 10), 72–77 (2000).
   PubMed Web of Science ®Google Scholar
• Poole C, Gardiner J, Twelves C et al. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients. Cancer Chemother. Pharmacol.49(3), 225–234 (2002).
   PubMed Web of Science ®Google Scholar
• Budman DR, Meropol NJ, Reigner B et al. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J. Clin. Oncol.16(5), 1795–1802 (1998).
   PubMed Web of Science ®Google Scholar
• Mackean M, Planting A, Twelves C et al. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J. Clin. Oncol.16(9), 2977–2985 (1998).
   PubMed Web of Science ®Google Scholar
• Cassidy J, Dirix L, Bissett D et al. A Phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors. Clin. Cancer Res.4(11), 2755–2761 (1998).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Findlay M, Osterwalder B et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized Phase II study. J. Clin. Oncol.18(6), 1337–1345 (2000).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Twelves C, Cassidy J et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large Phase III study. J. Clin. Oncol.19(21), 4097–4106 (2001).
   PubMed Web of Science ®Google Scholar
• Hoff PM, Ansari R, Batist G et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized Phase III study. J. Clin. Oncol.19(8), 2282–2292 (2001).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Hoff PM, Harper P et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, Phase III trials. Br. J. Cancer90(6), 1190–1197 (2004).
   PubMed Web of Science ®Google Scholar
• Cassidy J, Twelves C, Van Cutsem E et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann. Oncol.13(4), 566–575 (2002).
   PubMed Web of Science ®Google Scholar
• de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol.18(16), 2938–2947 (2000).
   PubMed Web of Science ®Google Scholar
• Saltz LB,Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med.343, 905–914 (2000).
   PubMed Web of Science ®Google Scholar
• Gil-Delgado M, Bastian G, Pauleet B et al. Final results of a pharmacokinetic (PK) study of capecitabine (X) in combination with oxaliplatin (O) for patients (pts) with metastatic colorectal cancer (MCRC). Am. Soc. Clin. Oncol.23(16 Suppl. 1) (2005) (Abstract 3685).
   Google Scholar
• Diaz-Rubio E, Evans T R, Tabemero J. Capecitabine (Xeloda) in combination with oxaliplatin: a Phase I, dose-escalation study in patients with advanced or metastatic solid tumors. Ann. Oncol.13, 558–565 (2002).
   PubMed Web of Science ®Google Scholar
• Cassidy J, Tabernero J, Twelves C et al. XELOX (capecitabine plus oxaliplatin), active first-line therapy for patients with metastatic colorectal cancer. J. Clin. Oncol.22(11), 2084–2091 (2004).
   PubMed Web of Science ®Google Scholar
• Sumpter K, Harper-Wynne C, Cunningham D, Gillbanks A, Norman AR, Hill M. Oxaliplatin and capecitabine chemotherapy for advanced colorectal cancer: a single institution’s experience. Clin. Oncol. (R. Coll. Radiol.)15(5), 221–226 (2003).
   Google Scholar
• Makatsoris T, Kalofonos HP, Aravantinos G et al. A Phase II study of capecitabine plus oxaliplatin (XELOX), a new first-line option in metastatic colorectal cancer. Int. J. Gastrointest. Cancer35(2), 103–109 (2005).
   PubMedGoogle Scholar
• Scheithauer W, Kornek GV, Raderer M et al. Randomized multicenter Phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol.21(7), 1307–1312 (2003).
   PubMed Web of Science ®Google Scholar
• Cassidy J, Clarke S, Rubio E et al. XELOX vs. FOLFOX4: Efficacy results from XELOX-1/NO16966, a randomized Phase III trial in first-line metastatic colorectal cancer (MCRC). Am. Soc. Clin. Oncol. Presented at: Gastrointestinal Cancers Symposium. Orlando, FL, USA, 19–21 January 2007 (Abstract 270).
   Google Scholar
• Hochster HS. Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer. Semin. Oncol.33(5 Suppl. 10), S8–S14 (2006).
   Google Scholar
• Rea DW, Nortier JW, Ten Bokkel Huinink WW et al. A Phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. Ann. Oncol.16(7), 1123–1132 (2005).
   PubMedGoogle Scholar
• Nishimura G. Evidence of increased effect of thymidine phosphorylase by irinotecan: a proof for the intensified efficacy by combination with irinotecan and capecitabine. Am. Soc. Clin. Oncol. Presented at: Gastrointestinal Cancers Symposium. San Francisco, CA, USA, 26–28 January 2006 (Abstract 298).
   Google Scholar
• Patt Y. Final efficacy and safety findings from a Phase II trial of capecitabine (X) plus irinotecan (XELIRI) as first-line treatment for metastatic colorectal cancer (MCRC). Eur. Soc. Med. Oncol. Congress (2004) (Abstract 286).
   Google Scholar
• Bajetta E, Di Bartolomeo M, Mariani L et al. Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer100(2), 279–287 (2004).
   PubMed Web of Science ®Google Scholar
• Gold P. Capecitabine and irinotecan as 1st line therapy for patients with metastatic colorectal cancer: Phase II study preliminary results. Am. Soc. Clin. Oncol. (2003) (Abstract 1158).
   Google Scholar
• Munoz A, Salud A, Giron C, Munas A, Bunilo M, Arizcun A. Randomised Phase III trial comparing irinotecan plus capecitabine (XELIRI regimen) vs. irinotecan, 5-FU and folinic acid (Saltz regimen) as first-line treatment in patients (pts) with metastatic colorectal cancer (MCRC). Ann. Oncol.17(Suppl. 9) (2006) (Abstract 345P).
   Google Scholar
• Fuchs CS, Marshall J, Mitchell EP, Wierzbicki R, Ganju V, Jeffery M. A randomised trial of first-line irinotecan/fluoropyrimidine combinations with or without celecoxib in metastatic colorectal cancer (BICC-C). Am. Soc. Clin. Oncol. (2006) (Abstract 3506).
   Google Scholar
• Kohne C, de Greve C, Bokemeyer I, Lang P, Vergauwe D, Braumann M. Capecitabine plus irinotecan versus 5-FU/FA/irinotecan +/- celecoxib in the first line treatment of metastatic colorectal cancer. Safety results of the prospective multicenter EORTC Phase III study 40015. Am. Soc. Clin. Oncol. (2005) (Abstract 3525).
   Google Scholar
• Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet345(8955), 939–944 (1995).
   PubMed Web of Science ®Google Scholar
• O’Connell MJ, Mailliard JA, Kahn MJ et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J. Clin. Oncol.15(1), 246–250 (1997).
   PubMed Web of Science ®Google Scholar
• Moertel CG, Fleming TR, Macdonald JS et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann. Intern. Med.122(5), 321–326 (1995).
   PubMed Web of Science ®Google Scholar
• Scheithauer W, McKendrick J, Begbie S et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, Phase III trial. Ann. Oncol.14(12), 1735–1743 (2003).
   PubMed Web of Science ®Google Scholar
• Twelves C, Wong A, Nowacki MP et al. Capecitabine as adjuvant treatment for stage III colon cancer. N. Engl. J. Med.352(26), 2696–2704 (2005).
   PubMed Web of Science ®Google Scholar
• Schmoll HJ, Cartwright T, Tabernero J et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J. Clin. Oncol.25(1), 102–109 (2007).
   PubMed Web of Science ®Google Scholar
• Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J. Clin. Oncol.15(1), 110–115 (1997).
   PubMed Web of Science ®Google Scholar
• Twelves C, Boyer M, Findlay M Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a Phase III trial conducted in patients with advanced colorectal carcinoma. Eur. J. Cancer37(5), 597–604 (2001).
   PubMed Web of Science ®Google Scholar
• Cassidy J, Douillard JY, Twelves C et al. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes’ C colon cancer: the X-ACT trial. Br. J. Cancer94(8), 1122–1129 (2006).
   PubMed Web of Science ®Google Scholar